Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 14; no. 7; p. 636
• Main Authors: Tassone, Giusy, Landi, Giacomo, Linciano, Pasquale, Francesconi, Valeria, Tonelli, Michele, Tagliazucchi, Lorenzo, Costi, Maria Paola, Mangani, Stefano, Pozzi, Cecilia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.06.2021; MDPI
• Subjects: Chagas disease; cycloguanil; derivatives; Dihydrofolate reductase; Drug resistance; Metabolism; Parasites; Parasitic diseases; Protozoan enzymes; pteridine reductase; pyrimethamine; Tropical diseases; Trypanosoma brucei; Vitamin B; X-ray crystallography; derivatives; pyrimethamine; pteridine reductase; structure–activity relationship; dual inhibitor; Trypanosoma brucei; cycloguanil; antifolate drug; dihydrofolate reductase
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph14070636

and parasites are the etiological agents of various threatening neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, and various types of leishmaniasis. Recently, meaningful progresses in the treatment of HAT, due to ( ), have been achieved by the introduction of fexinidazole and the combination therapy eflornithine-nifurtimox. Nevertheless, due to drug resistance issues and the exitance of animal reservoirs, the development of new NTD treatments is still required. For this purpose, we explored the combined targeting of two key folate enzymes, dihydrofolate reductase (DHFR) and pteridine reductase 1 (PTR1). We formerly showed that the DHFR inhibitor cycloguanil (CYC) also targets PTR1, although with reduced affinity. Here, we explored a small library of CYC analogues to understand how their substitution pattern affects the inhibition of both PTR1 and DHFR. Some novel structural features responsible for an improved, but preferential, ability of CYC analogues to target PTR1 were disclosed. Furthermore, we showed that the known drug pyrimethamine (PYR) effectively targets both enzymes, also unveiling its binding mode to PTR1. The structural comparison between PYR and CYC binding modes to PTR1 and DHFR provided key insights for the future design of dual inhibitors for HAT therapy.